Literature DB >> 8610417

Relevance and risk factors of enterococcal bacteremia following liver transplantation.

R Patel1, A D Badley, J Larson-Keller, W S Harmsen, D M Ilstrup, R H Wiesner, J L Steers, R A Krom, D Portela, F R Cockerill, C V Paya.   

Abstract

To analyze the clinical characteristics of and identify specific risk factors for enterococcal bacteremia following liver transplantation, we performed a study in 405 consecutive liver transplantation recipients prophylaxed with a selective bowel decontamination regimen. Seventy enterococcal bacteremias in 52 patients were identified. Enterococcus faecalis (50) outnumbered Enterococcus faecium isolates (18), and 49% of enterococcal bacteremias were polymicrobial. Biliary tree complications were present in 34% of enterococcal bacteremias. Of the 15 deaths (29%) among the patients with enterococcal bacteremia, 4 were directly associated with enterococcal bacteremia. In a multivariate analysis, Roux-en-Y choledochojejunostomy (P=0.005), a cytomegalovirus-seropositive donor (P=0.013), prolonged transplantation time (P=0.02), and biliary stricturing (P=0.016) were identified as significant risk factors. Other risk factors identified in a univariate analysis included primary sclerosing cholangitis (P=0.009) and symptomatic cytomegalovirus infection (P=0.008). Enterococcal bacteremia is a frequent infectious complication in liver transplantation recipients receiving selective bowel decontamination. Its association with cytomegalovirus and biliary tree abnormalities suggest specific areas for prophylactic intervention.

Entities:  

Mesh:

Year:  1996        PMID: 8610417     DOI: 10.1097/00007890-199604270-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Critical issues in the clinical management of complicated intra-abdominal infections.

Authors:  Stijn Blot; Jan J De Waele
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Are there patients with peritonitis who require empiric therapy for enterococcus?

Authors:  S Harbarth; I Uckay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-21       Impact factor: 3.267

3.  Biographical Feature: Robin Patel, M.D.(C.M.), D(ABMM), F(AAM), FIDSA, FACP.

Authors:  Erik Munson
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

4.  Essentials for selecting antimicrobial therapy for intra-abdominal infections.

Authors:  Stijn Blot; Jan J De Waele; Dirk Vogelaers
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

5.  Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.

Authors:  Agnes Loo Yee Cheah; Trisha Peel; Benjamin P Howden; Denis Spelman; M Lindsay Grayson; Roger L Nation; David C M Kong
Journal:  BMC Infect Dis       Date:  2014-06-28       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.